Inflammatory Bowel Disease
Found 20 articles
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organization
Surrozen Inc. announced today that new data from its inflammatory bowel disease (IBD) program, including preclinical studies of SZN-1326 showing superior activity compared to therapeutics currently used in treatment, were presented during the 16 th Congress of the European Crohn’s and Colitis Organisation.
Lyfebulb and Arena Pharmaceuticals Announce the Finalists for the 2021 Imagining Life Without Limits - An Inflammatory Bowel Disease Innovation Challenge
Lyfebulb, and Arena Pharmaceuticals, a company focused on developing innovative therapeutics for immune-mediated conditions, announce the ten patient entrepreneurs selected as finalists for the 2021 Imagining Life Without Limits – An Inflammatory Bowel Disease Innovation Challenge.
Lynk Pharmaceuticals Co., Ltd. announced today that its new Class I innovative drug LNK01003, has been approved by National Medical Products Administration (NMPA) for clinical trials of inflammatory bowel disease (IBD).
Progenity, Inc. today announced the formation of its Inflammatory Bowel Disease Clinical Advisory Board.
Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease
Synlogic, Inc. announced today that it has entered into a research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic™ medicine for the treatment of inflammatory bowel disease (IBD).
Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company , today announced that it intends to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel disease
Rodeo Therapeutics Nominates First-in-Class Oral Development Candidate for Inflammatory Bowel Disease
Rodeo Therapeutics Nominates First-in-Class Oral Development Candidate for Inflammatory Bowel Disease Rodeo Therapeutics nominates Candidate RTX-1688, a first-in-class oral small molecule therapy for tissue regeneration and repair, with inflammatory bowel disease as the initial indication and platform potential in other disease settings SEATTLE--( BUSINESS WIRE )-- Rodeo Therapeutics Corporation, a company developing small-molecule therapies designe
Alfasigma USA, Inc. Engages Indegene, Inc. to Expand the Promotion of ZELNORM® to Healthcare Professionals in the United States
Alfasigma USA, Inc. today announced a strategic deal with Indegene, Inc., a global life sciences and healthcare solutions provider, to co-promote its Irritable Bowel Syndrome with Constipation (IBS-C) drug, ZELNORM ® (tegaserod), to prescribers across the United States. ZELNORM ® was approved for reintroduction by the FDA for the treatment of adult women less than 65 years of age with IBS-C in March 2019. Alfasigma acquired the brand in
Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering Use of Thykamine™ for the Treatment of Ulcerative Colitis
Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) (TSXv:GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 15/772,155, titled, "Thylakoid Extract Composition and Form
In the deal, Boehringer acquired worldwide exclusive rights to Enleofen’s preclinical interleukein-11 (IL-11) platform.
Innovation Pharmaceuticals: Patient Screening for Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program On Track for Early January
Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce that patient screening for its Phase 1 trial to investigate the use in healthy volunteers of delayed release tablets for colonic delivery of oral Brilacidin for treating Ulcerative Colitis,
The FDA approved extended-release 11 mg and 22 mg tablets as a once-daily treatment from the chronic inflammatory condition.
Innovation Pharmaceuticals Granted Regulatory Approval to Start Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Company Aims to Capture Large Market Opportunity for Novel Oral IBD Drug Candidates
Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Company approval to start its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers.
Engitix and Morphic Enter Research Collaboration to Identify ECM-Related Targets in Fibrostenotic Inflammatory Bowel Disease (IBD)
Engitix Ltd and Morphic Therapeutic announce that they have entered into a research collaboration to identify ECM-related drug targets in fibrostenotic inflammatory bowel disease, an intestinal fibrosis complication that affects approximately 30 per cent of Crohn’s Disease patients.
Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD)
Eli Lilly and Company's (NYSE: LLY) first digital health open innovation challenge, "Transforming IBD Care: Better Disease Monitoring, Management, and Care for People with Inflammatory Bowel Disease," has concluded, with HealthVoyager, an application developed by Boston Children's Hospital and Klick Health, being named the winner.
Researchers Working to Understand Why Some Patients with Autoimmune Diseases Develop Diabetes Ins...
11/21/2019A peculiarity of autoimmune diseases is that they have many genes in common, but they develop differently.
The drug showed what the company is calling a “substantial improvement in this symptom-driven score” at the 12-week point, but it did not differentiate from placebo.
Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration's (FDA) approval of STELARA® (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis.
Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFα Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease
Latest real-world data presented at UEG Week 2019 complements the extensive body of clinical evidence for the gut-selective biologic vedolizumab in biologic-naïve patients with moderately to severely active ulcerative colitis or Crohn’s disease